Leerink Partnrs Has Negative View of Bruker FY2025 Earnings

Bruker Corporation (NASDAQ:BRKR - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Bruker in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $2.42 per share for the year, down from their previous estimate of $2.46. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.50 EPS, FY2026 earnings at $2.70 EPS and FY2027 earnings at $3.03 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The business's revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the company earned $0.53 earnings per share.

BRKR has been the topic of several other reports. Bank of America cut their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Wells Fargo & Company lowered their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Citigroup cut Bruker from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $50.00 to $40.00 in a research report on Thursday, May 22nd. Barclays lowered their price objective on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, UBS Group lowered their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of "Hold" and a consensus price target of $52.89.

Bruker Trading Down 3.9%

NASDAQ:BRKR traded down $1.64 during mid-day trading on Friday, reaching $40.55. 2,181,482 shares of the company's stock traded hands, compared to its average volume of 1,788,987. Bruker has a 12-month low of $34.10 and a 12-month high of $72.94. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of 77.98, a PEG ratio of 2.73 and a beta of 1.18. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74. The company has a 50 day moving average price of $39.43 and a 200-day moving average price of $44.89.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. Bruker's payout ratio is presently 38.46%.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $38.36 per share, with a total value of $100,042.88. Following the acquisition, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 27.30% of the company's stock.

Institutional Trading of Bruker

Several institutional investors have recently added to or reduced their stakes in BRKR. Pinnacle Bancorp Inc. purchased a new position in Bruker during the first quarter valued at approximately $29,000. Allworth Financial LP lifted its stake in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after buying an additional 745 shares during the period. Parallel Advisors LLC lifted its stake in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company's stock worth $37,000 after buying an additional 347 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Bruker during the first quarter worth $42,000. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.